IL-6 can drive a Th17 phenotype from naïve T cells (Bettelli et al., 2006), and reduce regulatory T cells (Tregs) (Korn et al., 2008; Kimura and Kishimoto, 2010; Schneider et al., 2013) in EAE and MS patients. This evidence concerns the gene IL6 and myeloid sarcoma.